Minute Insight: Theranica’s Wearable Earns Expanded FDA Clearance For Preventing Migraines
Theranica’s expanded US FDA clearance allows the company to market its prescription-based wearable as both an acute and preventive treatment for migraine headaches.
You may also be interested in...
Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.
Medicare beneficiaries suffering from migraines will soon have access to an innovate drug-free treatment at the touch of their smartphones.
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.